A patient who has breast cancer tells the nurse that a cousin who had breast cancer received trastuzamab (Herceptin) and wonders why this drug is not given to her. The nurse will explain that her cancer cells do not have
a. significant HER2 receptors.
b. epidermal growth factor receptor-tyrosine kinase.
c. the BRCA1 suppressor gene.
d. VGEF proteins.
ANS: A
Trastuzamab acts by binding to the HER2 protein on the surface of cancer cells that overexpress this receptor. If patients do not have this overexpression, this targeted therapy will not work. Gefitinib is used when EGFR-TK are present. Bevacizumab is used when VGEF proteins are present.
You might also like to view...
A patient has been diagnosed with tuberculosis and will soon begin first-line drug treatment. How will rifampin most likely be administered to this patient by the nurse?
A) Orally, with food B) Orally, on an empty stomach C) Intramuscularly D) Intravenously, as bolus
When assessing a client's uterine fundus during the fourth stage of labor, the nurse palpates a soft, uncontracted ("boggy") fundus. Which of the following actions would the nurse perform next?
A) Instruct the client to exercise B) Gently massage the fundus C) Suggest complete bed rest D) Suggest avoiding lifting weight
A nurse is weighing a breastfed 6-month-old infant who has been brought to the pediatrician's office for a scheduled visit. The infant's weight at birth was 6 lb 8 oz. The nurse notes that the infant now weighs 13 lb. Which action should the nurse take?
A. Tell the mother that the infant's weight is increasing as expected B. Tell the mother to decrease the daily number of feedings because the weight gain is excessive C. Tell the mother that semisolid foods should not be introduced until the infant's weight stabilizes D. Tell the mother that the infant should be switched from breast milk to formula because the weight gain is inadequate
FICA tool
What will be an ideal response?